Online Purchasing Account You are logged on as Guest. LoginRegister a New AccountShopping cart (Empty)
United States 

Resveratrol's metabolic effects include inhibition of PDE 4 and activation of sirtuin 1

Resveratrol is a natural product found in various fruits and in red wine. Dr. Sung-Jun Park, from the National Institutes of Health in Bethesda, MD, and colleagues have demonstrated that by inhibiting phosphodiesterase (PDE) 4 in mouse skeletal muscle, resveratrol initiates a series of intracellular processes leading to the indirect activation of sirtuin 1 (Sirt1). (Park et al, (2012) Cell 148(3):421-33). Resveratrol administration results in increased cAMP levels, due to competitive inhibition of cAMP-degrading PDEs. Furthermore, the metabolic benefits of resveratrol treatment can be duplicated by selectively inhibiting PDE4 using rolipram, a selective cell-permeable PDE4 inhibitor. Benefits include prevention of diet-induced obesity, increased mitochondrial function, enhanced physical endurance, and glucose tolerance. The new research suggests that PDE4 inhibitors may be useful for treating metabolic diseases such as type-2 diabetes, inflammation and cancer, as well as aging-related disorders, such as Alzheimer’s disease.

Enzo Life Sciences offers a comprehensive portfolio of inhibitors, recombinant proteins and assay kits relevant to elucidating the roles of PDE4 and Sirt1 in metabolism and disease.

 

Related Products

Resveratrol 

Antioxidant. SIRT1 activator.
501-36-0, ≥98% (HPLC) | Print as PDF
 
BML-FR104-0100 100 mg 58.00 USD
 
BML-FR104-0500 500 mg 249.00 USD
Do you need bulk/larger quantities?
 

Triacetyl resveratrol 

SIRT activator
42206-94-0, Synthetic., ≥98% (TLC) | Print as PDF
 
BML-FR119-0010 10 mg 67.00 USD
Do you need bulk/larger quantities?
 

Rolipram 

PDE inhibitor
61413-54-5, ≥98% (TLC) | Print as PDF
 
BML-PD175-0010 10 mg 69.00 USD
 
BML-PD175-0050 50 mg 296.00 USD
Do you need bulk/larger quantities?
 

R-(-)-Rolipram 

PDE inhibitor
85416-75-7, ≥98% (HPLC) | Print as PDF
 
BML-PD177-0005 5 mg 173.00 USD
Do you need bulk/larger quantities?
 

S-(+)-Rolipram 

PDE inhibitor
85416-73-5, ≥98% (HPLC) | Print as PDF
 
BML-PD178-0005 5 mg Inquire for pricing
Do you need bulk/larger quantities?
 

RO-20-1724 

PDE inhibitor
29925-17-5, ≥99% (TLC) | Print as PDF
 
BML-EI117-0100 100 mg 119.00 USD
 
BML-EI117-1000 1 g 363.00 USD
Do you need bulk/larger quantities?
 

SQ 20009 

PDE inhibitor
35838-58-5, ≥98% (HPLC) | Print as PDF
 
BML-PD130-0005 5 mg 64.00 USD
 
BML-PD130-0025 25 mg 269.00 USD
Do you need bulk/larger quantities?
 

Zardaverine 

PDE inhibitor
101975-10-4, ≥98% (HPLC) | Print as PDF
 
BML-PD195-0005 5 mg 88.00 USD
 
BML-PD195-0025 25 mg 379.00 USD
Do you need bulk/larger quantities?
 

PDE4D (catalytic domain) (human), (recombinant) 

Produced in E. coli. Active catalytic domain of phosphodiesterase 4D. | Print as PDF
 
BML-SE523-0020 20 µg 468.00 USD
Do you need bulk/larger quantities?
 

PDE4A (catalytic domain) (human), (recombinant) 

Produced in E. coli. Active catalytic domain of phosphodiesterase 4A. | Print as PDF
 
BML-SE521-0020 20 µg 468.00 USD
Do you need bulk/larger quantities?
 

SIRT1 (human), (recombinant) (His-tag) 

Highly active
Produced in E. coli. Recombinant SIRT1 from human cDNA containing an N-terminal His-tag. | Print as PDF
 
BML-SE239-0100 100 U 341.00 USD
Do you need bulk/larger quantities?
 

Cyclic Nucleotide Phosphodiesterase assay kit 

Unique colorimetric assay used to screen inhibitors and modulators of cyclic nucleotide phosphodiesterase activity.
Colorimetric detection, HTS, Activity assay | Print as PDF
 
BML-AK800-0001 96 wells 412.00 USD
Do you need bulk/larger quantities?
 

FLUOR DE LYS® SIRT1 fluorometric drug discovery assay kit 

First-to-market by the leader in Epigenetics research tools
Fluorescent detection, HTS, Activity assay, Cell-based assays | Print as PDF
 
BML-AK555-0001 96 wells 656.00 USD
Do you need bulk/larger quantities?
 

Recommend this page

 
For Research Use Only. Not for use in diagnostic procedures.
Keep in touch

©2018 Enzo Life Sciences, Inc.,